$2.27
5.29%
Downside
Day's Volatility :13.31%
Upside
8.47%
13.82%
Downside
52 Weeks Volatility :91.59%
Upside
90.24%
Period | Biocardia Inc | Index (Russel 2000) |
---|---|---|
3 Months | -38.98% | 0.0% |
6 Months | -64.64% | 0.0% |
1 Year | -69.97% | 0.0% |
3 Years | -94.96% | -22.3% |
Market Capitalization | 7.9M |
Book Value | - $0.92 |
Earnings Per Share (EPS) | -5.33 |
PEG Ratio | 0.0 |
Wall Street Target Price | 25.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -54966.67% |
Return On Assets TTM | -115.93% |
Return On Equity TTM | -703.62% |
Revenue TTM | 428.0K |
Revenue Per Share TTM | 0.26 |
Quarterly Revenue Growth YOY | -93.0% |
Gross Profit TTM | -7.5M |
EBITDA | -8.5M |
Diluted Eps TTM | -5.33 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.06 |
EPS Estimate Next Year | -1.27 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 1001.32%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 625.0K | ↑ 30.48% |
Net Income | -13.9M | ↑ 12.71% |
Net Profit Margin | -2.2K% | ↑ 350.0% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 710.0K | ↑ 13.6% |
Net Income | -14.8M | ↑ 6.83% |
Net Profit Margin | -2.1K% | ↑ 132.34% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 145.0K | ↓ 79.58% |
Net Income | -15.0M | ↑ 1.26% |
Net Profit Margin | -10.3K% | ↓ 8261.1% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.0M | ↑ 600.0% |
Net Income | -12.6M | ↓ 15.89% |
Net Profit Margin | -1.2K% | ↑ 9104.83% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.4M | ↑ 33.2% |
Net Income | -11.9M | ↓ 5.61% |
Net Profit Margin | -881.14% | ↑ 362.31% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 477.0K | ↓ 64.72% |
Net Income | -11.6M | ↓ 2.87% |
Net Profit Margin | -2.4K% | ↓ 1544.65% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 64.0K | ↓ 39.62% |
Net Income | -3.5M | ↑ 14.94% |
Net Profit Margin | -5.5K% | ↓ 2590.21% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 43.0K | ↓ 32.81% |
Net Income | -3.4M | ↓ 1.95% |
Net Profit Margin | -8.0K% | ↓ 2506.54% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 357.0K | ↑ 730.23% |
Net Income | -2.6M | ↓ 24.82% |
Net Profit Margin | -721.01% | ↑ 7241.78% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.0K | ↓ 96.36% |
Net Income | -2.1M | ↓ 19.5% |
Net Profit Margin | -15.9K% | ↓ 15217.45% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 55.0K | ↑ 323.08% |
Net Income | -2.3M | ↑ 9.41% |
Net Profit Margin | -4.1K% | ↑ 11816.64% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 3.0K | ↓ 94.55% |
Net Income | -1.6M | ↓ 27.39% |
Net Profit Margin | -54.9K% | ↓ 50744.85% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 6.4M | ↓ 52.6% |
Total Liabilities | 2.6M | ↑ 8.79% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 7.7M | ↑ 19.65% |
Total Liabilities | 5.3M | ↑ 102.21% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 23.4M | ↑ 205.08% |
Total Liabilities | 4.2M | ↓ 19.97% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 15.7M | ↓ 32.9% |
Total Liabilities | 5.3M | ↑ 25.78% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 9.8M | ↓ 37.7% |
Total Liabilities | 4.9M | ↓ 8.27% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.0M | ↓ 69.5% |
Total Liabilities | 4.6M | ↓ 6.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.1M | ↓ 27.21% |
Total Liabilities | 5.2M | ↑ 6.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.4M | ↓ 10.37% |
Total Liabilities | 4.8M | ↓ 9.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.7M | ↓ 41.35% |
Total Liabilities | 4.4M | ↓ 7.3% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.0M | ↓ 20.28% |
Total Liabilities | 4.6M | ↑ 4.15% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.7M | ↓ 10.31% |
Total Liabilities | 5.0M | ↑ 7.93% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.9M | ↑ 7.88% |
Total Liabilities | 4.9M | ↓ 2.08% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.1M | ↑ 27.66% |
Investing Cash Flow | -66.0K | ↓ 51.47% |
Financing Cash Flow | 3.8M | ↑ 2541.67% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.4M | ↓ 14.67% |
Investing Cash Flow | -146.0K | ↑ 121.21% |
Financing Cash Flow | 9.8M | ↑ 158.1% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.4M | ↑ 30.83% |
Investing Cash Flow | -32.0K | ↓ 78.08% |
Financing Cash Flow | 28.2M | ↑ 187.34% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.4M | ↓ 16.11% |
Investing Cash Flow | -116.0K | ↑ 262.5% |
Financing Cash Flow | 1.9M | ↓ 93.1% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.6M | ↑ 1.88% |
Investing Cash Flow | -70.0K | ↓ 39.66% |
Financing Cash Flow | 5.1M | ↑ 163.07% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.6M | ↓ 14.58% |
Investing Cash Flow | -10.0K | ↑ 400.0% |
Financing Cash Flow | 64.0K | ↓ 98.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.2M | ↑ 23.09% |
Investing Cash Flow | -2.0K | ↓ 80.0% |
Financing Cash Flow | 2.6M | ↑ 3964.06% |
Sell
Neutral
Buy
Biocardia Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Biocardia Inc | -20.35% | -64.64% | -69.97% | -94.96% | -96.85% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Biocardia Inc | NA | NA | 0.0 | -5.06 | -7.04 | -1.16 | NA | -0.92 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Biocardia Inc | Buy | $7.9M | -96.85% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Biocardia Inc
Revenue is down for the last 2 quarters, 55.0K → 3.0K (in $), with an average decrease of 94.6% per quarter
Netprofit is up for the last 2 quarters, -2.26M → -1.64M (in $), with an average increase of 37.7% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 107.1%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 164.2%
Vanguard Group Inc
Geode Capital Management, LLC
Brown Advisory Holdings Inc
Advisor Group Holdings, Inc.
State Street Corporation
Pingora Partners LLC
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
Organization | Biocardia Inc |
Employees | 16 |
CEO | Dr. Peter A. Altman Ph.D. |
Industry | Biotechnology |
A Spac I Acquisition Corp
$2.27
-9.2%
Keyarch Acquisition Corp
$2.27
-9.2%
Connexa Sports Technologies Inc
$2.27
-9.2%
Us Value Etf
$2.27
-9.2%
First Wave Biopharma Inc
$2.27
-9.2%
Global X Msci Next Emerging
$2.27
-9.2%
Fat Projects Acquisition Corp
$2.27
-9.2%
Capital Link Global Fintech
$2.27
-9.2%
Applied Uv Inc
$2.27
-9.2%